Company profile

Azurity Pharmaceuticals

Specialty/reformulated branded generics (BiDil)

Privately held: no public share price · USA

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Alvesco
Approved
Glucocorticoid receptorSmall molecule
Asthma
Ferumoxytol(Feraheme)
Approved
IV iron replacement therapyBiologic — subtype unspecified
Chronic Kidney Disease
Isosorbide dinitrate/hydralazine(BiDil)
Approved
Hydralazine/isosorbide dinitrate (fixed combination)Small molecule
Heart Failure
Zonisamide (Zonisade)(Zonisade)
Approved
Voltage-gated sodium and T-type calcium channelsSmall molecule
Epilepsy

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.